Quick Read How Could Management Fail So Badly One Of The Worst Performing Stocks Not Going To Get Better Investors rethink 'hands off' investing and decide to start making real money Hims & Hers Health (NASDAQ: HIMS) has had among the worst runs of any public company over the last year. And, there is little reason to think it will recover. The stock is down 47% in the previous year, and 29% so far this year. Buyers need to beware that they are not catching a falling knife. Matters are worse for p ...

Company Overview - PomDoctor is a Chinese online medical services platform founded in 2010, focusing on chronic disease management and pharmaceutical services [2] - The platform operates through internet-hospital services and a pharmaceutical supply chain, connecting patients to doctors for prescriptions and follow-ups [2] IPO Details - PomDoctor priced its IPO at $4 per American Depository Share (ADS), which is at the lower end of the indicated price range of $4.00 to $6.00 per ADS [3] - The company offered 5 million ADSs, with gross proceeds of $20 million intended for platform development, technology upgrades, and supply chain expansion [4] Market Potential - The online Chinese healthcare industry is projected to grow from approximately 540.7 billion yuan in 2022 to 1.5 trillion yuan by 2027, reflecting a compound annual growth rate (CAGR) of about 23.1% [5] - The Chinese telemedicine market is expected to expand from $7.14 billion in 2024 to $54.77 billion by 2033, with a CAGR of 23.50% [5] Initial Trading Performance - Following the IPO, PomDoctor's shares began trading approximately 12.5% above the IPO price, indicating strong demand and positive market reception [3]